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Introduction: The echinoderm microtubule-associated protein-like 
4 anaplastic lymphoma kinase (EML4-ALK) fusion gene has been 
identified as a potent oncogenic driver in non–small-cell lung can-
cer, in particular adenocarcinoma (ADC). It defines a unique sub-
group of lung ADC, which may be responsive to ALK inhibitors. 
Detection of ALK rearrangement by fluorescence in situ hybrid-
ization (FISH) or reverse transcriptase polymerase chain reaction 
(RT-PCR) is considered to be the standard procedure, but each with 
its own limitation. We evaluated the practical usefulness of immuno-
histochemistry (IHC) to detect ALK expression as a reliable detec-
tion method of ALK rearrangement in lung ADC.
Methods: We tested 373 lung ADCs for ALK rearrangement by IHC and 
FISH. Multiplex RT-PCR was performed to confirm the fusion variants.
Results: Twenty-two of 373 lung ACs (5.9%) were positive for ALK 
immunoreactivity. ALK-positive tumor cells demonstrated strong 
and diffused granular staining in the cytoplasm. All the ALK IHC-
positive cases were confirmed to harbor ALK rearrangement, either 
by FISH, or RT-PCR. Two cases with positive ALK protein expres-
sion, but negative for breakapart FISH signal were shown to harbor 
EML4-ALK variant 1 by RT-PCR. None of the ALK IHC-negative 
cases were FISH-positive. In addition, we identified a novel EML4-
ALK fusion variant (E3:ins53A20), and its potent transformation 
potential has been confirmed by in vivo tumorigenicity assay.
Conclusion: IHC can effectively detect ALK rearrangement in 
lung cancer. It might provide a reliable and cost-effective diagnostic 
approach in routine pathologic laboratories for the identification of 
suitable candidates for ALK-targeted therapy.
Key Words: Lung adenocarcinoma, Anaplastic lymphoma kinase, 
Fusion transcript, Echinoderm microtubule-associated protein-like 4 
anaplastic lymphoma kinase, Immunohistochemistry, Fluorescence 
in situ hybridization, Immunohistochemistry.
(J Thorac Oncol. 2013;8: 883-891)
Anaplastic lymphoma kinase (ALK) was first identified as a 
fusion partner in t(2;5) chromosomal translocation associated 
with anaplastic large-cell lymphomas.1,2 Increasing evidence 
support the oncogenic role of ALK in both hematopoietic 
and nonhematopoietic tumors, including neuroblastoma, 
inflammatory myofibroblastic tumor, and non–small-cell lung 
cancer (NSCLC)3–6 by activation mutations or chromosomal 
translocation. Fusion of ALK with a variety of partner genes 
results in the expression of oncogenic chimeric proteins that 
lead to constitutive activation of the ALK kinase domain and the 
downstream signaling pathways. In lung cancer, a novel gene 
fusion of ALK and the echinoderm microtubule-associated 
protein-like 4 (EML4) was identified by in vitro transformation 
assays.6 Several EML4-ALK variants, resulting from fusion 
of various EML4 exons to ALK have been reported; all were 
transforming in vitro.7,8 Subsequent studies confirmed the 
presence of EML4-ALK fusion in 2% to 7% of NSCLC.8–13  
Other uncommon fusion partners for ALK, that is, KIF5B, 
TFG, and KLC1, have also been reported in NSCLC.14–16
ALK rearrangement has been demonstrated to be a 
potent oncogenic driver and a promising therapeutic target in 
NSCLC.6,17,18 It defines a distinct molecular subset of NSCLC, 
in particular adenocarcinoma (ADC) that can benefit by the 
treatment of ALK-inhibitors. Development of robust and 
reliable laboratory tests for predictive biomarkers is essential 
to select appropriate patients for targeted therapy. A variety 
of methods have been adopted for the detection of ALK 
rearrangement, including fluorescent in situ hybridization 
(FISH), immunohistochemistry (IHC) and reverse transcriptase 
polymerase chain reaction (RT-PCR). Currently, FISH analysis 
is the only approved diagnostic test for ALK rearrangement to 
detect breakapart signals. However, the apparatuses required 
for FISH analysis are not always readily available in routine 
diagnostic laboratories. ALK rearrangement frequently 
involves intrachromosomal inversion. The subtle changes may 
be difficult to interpret by FISH analysis sometimes, and have 
led to false-negative results.19,20 IHC has been considered an 
alternative to FISH, which can detect ALK rearrangements 
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independent of the fusion partners. The initial attempts were not 
encouraging, owing to a relatively low ALK protein expression 
in lung cancer with ALK rearrangement. Several studies using 
different antibodies and amplification strategies have recently 
been published.15,20–22 The amplified IHC protocols were highly 
sensitive but less specific. Therefore, a two-tier system, similar 
to human epidermal growth factor receptor 2, has been proposed 
for the evaluation of ALK IHC. Given the fact that ALK protein 
is not ubiquitously expressed in normal lung tissue and ALK-
negative lung cancers, it is thus likely that technical issues, 
rather than intrinsic biology, explain the false-positive results 
of ALK IHC in recent published reports. Optimal IHC protocol 
is warranted for the reliable detection. In the current study, we 
evaluated routine IHC staining method for the detection of 
ALK protein and compared it with FISH analysis. RT-PCR was 
performed to detect ALK fusion variants on the cases positive 
for ALK rearrangement either by IHC, or FISH analysis. We 
aimed to assess the sensitivity and specificity of ALK IHC in a 
cohort of Chinese patients with lung ADC.
MATERIALS AND METHODS
Clinical Samples
Patients diagnosed with lung ADC and the tumor speci-
mens subjected to epidermal growth factor receptor (EGFR) 
mutational analysis in Prince of Wales Hospital, Hong Kong, 
between 2007 and 2010 were included in this study. A total 
of 373 consecutive cases of lung ADC were retrieved from 
molecular diagnostic unit, Department of Anatomical and 
Cellular Pathology, Prince of Wales Hospital, Hong Kong. The 
histologic diagnosis was confirmed by pathologist (KFT). The 
patient demographic data and clinicopathologic characteris-
tics were obtained from medical records. The male to female 
ratio of the abovementioned lung cancer patients was 1.2/1. 
The median age of the patients was 65 years (range, 27–94 
years). On the basis of the 7th tumor, node, metastasis staging 
system for lung cancer, 154 patients had stage I diseases, 46 
patients had stage II, 86 patients had stage III, and 87 patients 
had stage IV diseases. The study protocol was approved by the 
Joint Chinese University of Hong Kong-New Territories East 
Clinical Research Ethics Committee, Hong Kong.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) archive tis-
sues from 315 cases were arranged in tissue array blocks. 
Hematoxylin and eosin–stained sections were used to define 
tumor areas, and three representative 1-mm cores were 
obtained from each case and inserted to a recipient paraffin 
block, using a tissue arrayer (Beecher Instruments; Silver 
Spring, MD). For the remaining 58 cases, only small biopsies 
or pleural fluid cytologic specimens were available. Because 
the materials were too scanty for tissue microarray (TMA) 
construction, whole sections were used for these cases
Different amplification and visualization systems for 
the IHC detection of ALK protein have been evaluated on a 
TMA comprising 57 lung ADCs. Polymer Refined Detection 
Kit (Leica Microsystems GmbH, Wetzlar, Germany) gave a 
slightly stronger staining intensity and was used for the study 
cases (please refer to Supplemental Digital Content 1, http://
links.lww.com/JTO/A410 for the details of the evaluation). 
Four-micrometer sections taken from each block were depa-
raffinized, rehydrated, and rinsed in distilled water. Antigen 
retrieval was done by using pressure cooker with 1-mM ethyl-
enediaminetetraacetic acid (pH 8.0) for 13 minutes. IHC was 
performed using monoclonal antibody against ALK (1:100, 
clone 5A4, Abcam, Cambridge, UK) and Polymer Refined 
Detection Kit (Leica Microsystems GmbH) on a Bond-max 
fully automated staining system (Leica Microsystems GmbH). 
All slides were counterstained with hematoxylin.
The cytoplasmic expression of ALK was assessed by 
assigning a proportion score and an intensity score.23 The 
proportion score was according to the proportion of tumor 
cells with positive cytoplasmic staining (0, none; 1, ≤ 10%; 
2, 10%–25%; 3, > 25%–50%; 4, > 50%). The intensity score 
was assigned for the intensity of positive tumor cells (0, none; 
1, weak; 2, moderate; 3, strong). Representative images of 
the staining intensity are shown in Supplementary Figure 
1 (Supplemental Digital Content 1, http://links.lww.com/
JTO/A410). The cytoplasmic score of ALK was the product 
of proportion and intensity scores, ranging from 0 (0 × 0) to 
12 (4 × 3). The cytoplasmic expression was categorized into 
negative (score 0), 1+ (score 1–3), 2+ (score 4–6), and 3+ 
(score 7–12). The slides were assessed blindly by two investi-
gators (JHMT and AWHC) and the inter-rater reliability was 
determined by kappa statistics. Consensus was established by 
jointly reviewing the case whenever there was a discrepancy.
Fluorescent In Situ Hybridization
FISH analysis was performed on the FFPE tumor tissues 
using a breakapart probe specific to the ALK locus (Vysis LSI 
ALK Dual Color, breakapart rearrangement probe; Abbott 
Molecular, Abbott Park, IL) according to the manufacturer’s 
instruction. In brief, 4-µm-thick sections were deparaffinized, 
dehydrated, immersed with Vysis pretreatment Solution 
(Abbott Molecular) at 80°C for 15 minutes, and treated with 
Protease Solution (Abbott Molecular) at 37°C for 20 minutes. 
Dual probe hybridization was performed using the LSI ALK 
dual-color probe, which hybridizes to the 2p23 locus with 
SpectrumOrange and SpectrumGreen on either side of the 
ALK gene breakpoint. After application of ALK probe mix-
ture, the slides were denatured at 75°C and then incubated at 
37°C overnight to allow hybridization. After washing the slides 
with Washing Buffer I and II (Abbott Molecular), the sec-
tions were counterstained with 4ʹ,6-diamidino-2-phenylindole 
(DAPI). ALK FISH was considered positive when more than 
15% of 100 or more analyzed cells showed splitting of the 
fluorescent probes flanking the ALK locus.
Reverse-Transcriptase Polymerase 
Chain Reaction
Total RNA from frozen tissue was extracted by TRIzol 
reagent (Life Technologies, Grand Island, NY). For FFPE 
samples, RecoverAll Total Nucleic Acid Isolation Kit for 
FFPE (Life Technologies) was used for RNA extraction. First, 
strand cDNA was obtained from 1 µg of total RNA, using 
Superscript III reverse transcriptase (Life Technologies). PCR 
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primers specific for all types of known ALK fusion transcripts, 
including all variants of EML4-ALK, kinesin family member 
5B (KIF5B)-ALK, TRK-fused gene (TFG)-ALK, and kinesin 
light chain 1 (KLC1)-ALK were designed using Primer3 
(version 0.4.0; Appliedbiosystems, Foster City, CA).24 The 
primer sequences are available on request. The amplified 
PCR products were subjected to direct sequencing, using ABI 
PRISM 3130xl DNA Sequencer (Applied Biosystems).
Identification of Genomic Breakpoint
Genomic DNA was extracted from frozen tissue, using 
QIAamp DNA mini kit (QIAGEN, Valencia, CA). PCR was 
carried out, using a forward primer at intron 3 of EML4 (5′- 
ATTGCACTGTTGCTTGTTGC-3′) and a reverse primer at 
intron 19 of ALK (5′- GTACACTGCAGGTGGGTGGT-3′), with 
the PCR SuperMix High Fidelity (Invitrogen, Grand Island, NY). 
The genomic breakpoint was confirmed by Sanger sequencing.
Cloning and Transfection
Full-length EML4-ALK new variant (E3;ins53A20) 
was amplified from tumor tissue by RT-PCR and inserted into 
pcDNA3.1(+) (Invitrogen) using standard cloning protocol. 
NIH3T3 cells were maintained in Dulbecco’s Modified Eagle 
Medium with 10% fetal bovine serum. The plasmids were trans-
fected into NIH3T3 cells using FuGENE HD (Roche, Mannheim, 
Germany). Expression of the chimeric protein was confirmed by 
Western blot analysis, as described previously, using polyclonal 
rabbit anti-ALK antibody (ZAL4, 1:5000, Invitrogen).25
In Vivo Tumorigenic Assay
NIH3T3 cells (1 × 106 cells suspended in 0.1-ml 
phosphate-buffered saline) transfected with EML4-ALK 
(E3;ins53A20) expression vector or empty vector were 
injected subcutaneously into the dorsal flank of five 4-week-
old male Balb/c nude mice (EML4–ALK-expressing clones 
on the right and vector control clones on the left). Tumor 
formation was examined after 3 weeks. The experiment was 
repeated thrice. The animal handling and all experimental pro-
cedures were approved by the Animal Ethics Committee of the 
Chinese University of Hong Kong.
Statistical Analysis
Statistical analysis of 2 × 2 contingency tables of cat-
egorical variables was performed using the χ2 test or Fisher’s 
exact test, as appropriate. The t test was performed to compare 
continuous variables between two groups. All statistical analy-
ses were carried out by using statistical program SPSS (ver-
sion 16.0; SPSS, Armonk, NY). A two-tailed p value of less 
than 0.05 was regarded as statistically significant.
RESULTS
Detection of ALK Rearrangement 
by IHC, FISH, and RT-PCR
We studied ALK rearrangement in a cohort of 373 
patients with lung ADC, using IHC and FISH. ALK protein 
expression was detected in 22 of 373 lung ADC patients 
(5.9%). Twenty of the ALK-positive tumors were identified 
FIGURE 1.  Representative ALK IHC images. Three cases of ALK IHC-positive cases are shown in upper panel and three 
negative cases are shown in lower panel. (ALK IHC, original magnification × 400). ALK, anaplastic lymphoma kinase; IHC, 
immunohistochemistry.
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from the TMA and two were identified on the whole-tissue 
section. In ALK IHC-positive cases, the tumor cells demon-
strated diffused cytoplasmic staining with moderate to strong 
intensity (Fig. 1). The ALK IHC-positive tumors showed 
a rather uniform staining pattern, with immunoreactivity in 
more than 90% tumor cells, and a proportional score of four. 
The intensity score in those ALK IHC-positive cases were 
either 2 (moderate), or 3 (strong). Combining the intensity 
score and proportion score, all 22 cases were categorized as 
3+ (Table 1). There was an excellent inter-rater agreement 
between two investigators when comparing categorized IHC 
scores: for score 0 versus score 1+ to 3+, κ = 0.911; for score 
0 and 1+ versus score 2+ and 3+, κ = 1. No ALK immunore-
activity was observed in normal alveolar or bronchial epithe-
lium, endothelial cells, smooth muscle cells, or stromal cells. 
The finding was consistent with the biological fact that ALK 
protein is not expressed in normal lung tissue.6
FISH analysis for ALK rearrangement was successful 
in 351 cases (94.1%). The success rate was 96.6% (56 of 58) 
for whole sections and 93.7% (295 of 315) for tissue arrays. 
Of them, 20 cases demonstrated breakapart signals that indi-
cated chromosomal rearrangements. The FISH-positive cases 
detected in tissue arrays were further validated using the cor-
responding whole-tissue sections. A representative case was 
shown in Figure 2A. Suboptimal tissue fixation, which could 
result in background autofluorescence, may contribute to 
the failure in FISH analysis.26 Notably, all 20 FISH-positive 
cases showed positive ALK protein expression as determined 
by IHC (Table 1). In two lung ADCs with strong and diffuse 
ALK immunoreactivity, only fusion signals or close proxim-
ity of the red and green signals were observed in tumor cells, 
despite repeated testing (Fig. 2B). We then repeated FISH 
analysis using additional tumor blocks. It was again negative 
for breakapart signals in both cases. These two cases were 
considered negative for FISH breakapart testing, which was 
defined by 15% or more split nuclei as indicative of an ALK 
rearrangement.
In addition to IHC and FISH, RT-PCR has been sug-
gested as a least subjective methodology to detect ALK rear-
rangements and to determine the specific fusion variants. A 
multiplex RT-PCR system was designed to capture all reported 
in-frame fusions of EML4-ALK, KIF5B-ALK, TFG-ALK, 
and KLC1-ALK. Frozen tumor tissues were available in four 
of 22 ALK IHC-positive cases, whereas only FFPE tissues 
were available for the remaining 18 cases. We successfully 
amplified EML4-ALK fusion transcripts from all four frozen 
tumors and 14 FFPE tumors. These included 10 cases with 
EML4-ALK variant 1, five cases with EML4-ALK variant 
3b, two cases with EML4-ALK variant 2, and a novel EML4-
ALK variant, which has not been reported previously.
Fusion transcript was not detected by RT-PCR in four 
FFPE tumors (Table 1). All were FISH-positive and IHC-
positive for ALK rearrangement. The failure to detect ALK 
fusion transcript in these FFPE tumor specimens might 
TABLE 1.  Details of ALK-Positive Lung Adenocarcinoma
Ref. No. Sex Age, Yr Smoking History Stage Specimen Type IHC Score FISH (% of Split Signal) RT-PCR
10946 F 69 NS IA FFPE 3+ −ve (3.5%) EML4-ALK V1 (E13/A20)
5134 F 82 ES IIIB FFPE 3+ −ve (2.1%) EML4-ALK V1 (E13/A20)
10482 M 43 ES IIA FFPE 3+ +ve (45.5%) EML4-ALK V1 (E13/A20)
17420 M 48 ES IA Frozen 3+ +ve (39.4%) EML4-ALK V1 (E13/A20)
5419 M 50 NS IIA Frozen 3+ +ve (65.5%) EML4-ALK V1 (E13/A20)
9328 M 51 CS IV FFPE 3+ +ve (72.8%) EML4-ALK V1 (E13/A20)
25648 M 49 NS IB FFPE 3+ +ve (59.3%) EML4-ALK V1 (E13/A20)
6 M 69 NS IV FFPE 3+ +ve (61.3%) EML4-ALK V1 (E13/A20)
20060 F 66 ES IIIA Frozen 3+ +ve (52.1%) EML4-ALK V1 (E13/A20)
1014 F 31 NA IV FFPE 3+ +ve (71.2%) EML4-ALK V1 (E13/A20)
15020 F 41 NS IB FFPE 3+ +ve (68.3%) EML4-ALK V2 (E20/A20)
20540 F 47 NS IV FFPE 3+ +ve (29.4%) EML4-ALK V2 (E20/A20)
7505 F 77 ES IIA FFPE 3+ +ve (85.5%) EML4-ALK V3b (E6/A20)
9346 F 44 NS IA FFPE 3+ +ve (55.4%) EML4-ALK V3b (E6/A20)
779 F 34 CS IA FFPE 3+ +ve (35.8%) EML4-ALK V3b (E6/A20)
2145 M 32 NA IV FFPE 3+ +ve (18.9%) EML4-ALK V3b (E6/A20)
14370 M 30 ES IV FFPE 3+ +ve (21.2%) EML4-ALK V3b (E6/A20)
3081 F 73 NS IIA Frozen 3+ +ve (32.3%) EML4-ALK New (E3/A20)
11940 M 60 NS IA FFPE 3+ +ve (66.4%) Neg
13620 M 54 NA IA FFPE 3+ +ve (28.3%) Neg
7162 M 74 NS IIIB FFPE 3+ +ve (38.4%) Neg
1953 F 39 NS IV FFPE 3+ +ve (42.5%) Neg
All specimens were surgical resections, except 5134 (pleural fluid cytologic specimen) and 1953 (pleural biopsy).
CS, chronic smoker; ES, exsmoker; EML4, echinoderm microtubule-associated protein-like; FFPE, formalin-fixed-paraffin-embedded; FISH, fluorescence in situ hybridization; 
IHC, immunohistochemistry; NA, not available; NS, nonsmoker; RT-PCR, reverse transcriptase-polymerase chain reaction.
887Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology®  •  Volume 8, Number 7, July 2013 Detection of ALK Rearrangement by IHC in Lung ADC
be because of poor RNA quality, or the presence of fusion 
variant(s) not assayed for by our RT-PCR system. Notably, in 
two ALK IHC-positive cases without breakapart FISH signal, 
fusion transcripts were detected by RT-PCR and confirmed to 
be EML4-ALK variant 1 by direct sequencing. We therefore, 
concluded that the FISH result was false-negative.
FISH is the current method of choice in clinical practice. 
If the sensitivity was calculated using FISH as standard pro-
cedure, IHC had a sensitivity of 100%. The two IHC-positive 
but FISH-negative cases were also proven to harbor EML4-
ALK fusion transcripts by RT-PCR, suggesting that IHC is 
even more sensitive than FISH in detecting ALK transloca-
tion. Moreover, all the IHC-positive cases could be confirmed 
as harboring ALK translocation either by FISH, or RT-PCR, 
indicating that ALK IHC is highly specific. In summary, we 
detected ALK protein expression in 22 of 373 lung ADCs 
(5.9%). All these tumors were confirmed to harbor ALK rear-
rangement either by FISH breakapart signal or by RT-PCR. 
False-negative results were found in two cases by FISH. We 
demonstrated a sensitive IHC-based assay, which showed ben-
efit over FISH analysis.
Clinicopathologic Characteristics of 
Lung ADC with ALK Rearrangement
Twenty-two ALK-positive patients, comprising 11 
men and 11 women, were included for study. None of the 
patients had exposure to ALK inhibitor, crizotinib. ALK 
rearrangement was found in eight of 157 smokers (5.1%) as 
compared with 11 of 176 nonsmokers (6.25%). There was 
no significant difference between tumor from smokers and 
nonsmokers with regard to ALK status (p = 0.65). Patients 
FIGURE 2. A, ALK, IHC, FISH, and 
sequence electropherogram of a lung 
adenocarcinoma with ALK rearrange-
ment (Ref. No. 15020). B, A repre-
sentative case (Ref. No. 10946) with 
discordant IHC and FISH results. The 
tumor was positive for ALK protein 
expression by IHC but FISH was nega-
tive. EML4-ALK variant 1 (fusion of 
EML4 exon 13 and ALK exon20) was 
detected by reverse transcriptase-poly-
merase chain reaction. ALK, anaplastic 
lymphoma kinase; EML4, echinoderm 
microtubule-associated protein-like; 
FISH, flouresence in situ hybridization; 
IHC, immunohistochemistry.
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with ALK-positive lung ADCs were significantly younger 
than those without (p < 0.0001; 52.9 ± 16.1 years versus 
64.5 ± 11.5 years). Histologically, the ALK-positive tumors 
displayed mixed growth patterns, including solid with mucin, 
papillary, acinia, and lepidic patterns. Signet ring cell compo-
nent was observed in 10 of 22 ALK-positive tumors (45.5%). 
Of them, four tumors showed more than 10% signet ring 
cells. Within the ALK-positive cohort, eight patients (36.4%) 
had stage I disease, four had stage II (18.2%), three had stage 
III (13.6%), and seven had stage IV (31.8%) diseases. Among 
the 373 cases, 159 cases (42.6%) harbored EGFR muta-
tion and 214 cases (57.4%) were EGFR wild type (wt). No 
EGFR mutation was identified in ALK-positive tumors (p < 
0.0001). A total of 192 cases were negative for both EGFR 
and ALK (designated wt/wt). There was no significant differ-
ence in tumor size, positive lymph node, distant metastasis, 
and pathologic stage between the ALK-positive and ALK-
negative groups (Table 2).
The follow-up data were available in 364 patients. At 
the time of evaluation, 211 patients (58%) were still alive, 
whereas 153 (42%) had died. The median follow-up time was 
52.0 months. There was no significant difference in overall 
survival (OS) times between the ALK-positive and ALK-
negative groups (median OS 55.8 ± 4.2 and 50.3 ± 4.1 months, 
respectively, p = 0.255; Supplementary Figure 2, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A410). When 
further stratifying the ALK-negative group, the median 
OS was 66.3 ± 4.7 months for EGFR-positive patients and 
46.2 ± 5.3 months for wt/wt (double negative: ALK-negative/
EGFR-negative) patients. Although there was a trend toward 
longer OS time in ALK-positive patients compared with wt/
wt patients, the difference was not statistically significant (p = 
0.076; Supplementary Fig. 3, Supplemental Digital Content 
1, http://links.lww.com/JTO/A410). In patients with stage IV 
diseases, median OS was 19.9 ± 8.1 months for ALK-positive 
group, compared with 25.1 ± 3.3 months for EGFR-positive 
group (p = 0.958), and 16.1 ± 3.0 months for wt/wt group (p = 
0.253; Supplementary Figure 4, Supplemental Digital Content 
1, http://links.lww.com/JTO/A410). We defined recurrence 
and metastasis as disease progression events for early-stage 
patients (stage I and II). Therefore, the median time to pro-
gression was 52.9 ± 16.6 months for early-stage ALK-positive 
patients, compared with 39.7 ± 9.6 months for EGFR-positive 
patients (p = 0.775), and 36.2 ± 11.7 months for wt/wt patients 
(p = 0.248; Supplementary Figure 5, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A410).
Identification of a Novel EML4-ALK Variant
A novel EML4-ALK fusion variant was detected in 
a lung ADC with ALK rearrangement. The tumor showed 
strong ALK protein expression and was also positive for ALK 
breakapart signal by FISH analysis. RT-PCR, using the primer 
set designed for EML4-ALK variant 5 (fusion between EML4 
exon 2 and ALK exon 20), yielded a PCR band larger than the 
expected product size. Direct sequencing of the PCR product 
revealed a fusion transcript, resulting from the connection of 
EML4 exon 3 to a position 53 base pair (bp) upstream of ALK 
exon 20 (Fig. 3). PCR direct sequencing of genomic DNA also 
revealed that EML4 was disrupted at a position 2241 bp (Chr 
2, NT 022184.15 21307898) downstream of exon 3 and was 
ligated to a position 60 bp (Chr 2, NT 022184.15, 8268341) 
upstream of exon 20 of ALK. The novel variant was desig-
nated E3;ins53A20 provisionally. The full-length sequence has 
been submitted to GenBank (accession number JQ828841). 
Because the frozen tumor tissue of this case was available, 
we amplified the full-length cDNA of variant E3;ins53A20 
from tumor and cloned into pcDNA3.1(+) expression vec-
tor. The transforming potential of variant E3;ins53A20 
was investigated by in vivo tumorigenicity assay. NIH 3T3 
mouse embryo fibroblast cells were transfected with variant 
E3;ins53A20 expression vectors and injected subcutaneously 
TABLE 2.  Frequency of ALK Rearrangement in Lung 
Adenocarcinoma and the Association with Clinicopathologic 
Characteristics
ALK Rearrangement
Characteristics + − p
N = 373
No. of cases 22 (5.9%) 351 (94.1%)
Sex NS
 Female 11 (50.0%) 160 (45.6%)
 Male 11 (50.0%) 191 (54.4%)
Age (yr) 52.9 ± 16.1 64.5 ± 11.5 <0.0001
Smoking status NS
 Nonsmoker 11 (50.0%) 165 (47.0%)
 Smoker 8 (36.4%) 148 (42.2%)
 Unknown 3 (13.6%) 38 (10.8%)
T stage NS
 T1 11 (50.0%) 106 (30.2%)
 T2 7 (31.8%) 139 (39.6%)
 T3 0 25 (7.1%)
 T4 4 (18.2%) 72 (20.5%)
Unknown — 9 (2.6%)
N stage NS
 N0 8 (36.4%) 188 (53.6%)
 N1 4 (18.2%) 35 (9.9%)
 N2 6 (27.3%) 87 (24.8%)
 N3 2 (9.1%) 19 (5.4%)
 Unknown 2 (9.1%) 22 (6.3%)
M stage NS
 M0 14 (63.6%) 239 (68.1%)
 M1 7 (31.8%) 68 (19.4%)
 Unknown 1 (4.6%) 44 (12.5%)
Stage NS
 1 8 (36.4%) 146 (41.6%)
 2 4 (18.2%) 42 (12.0%)
 3 3 (13.6%) 83 (23.6%)
 4 7 (31.8%) 80 (22.8%)
EGFR mutation <0.0001
+ 0 (0%) 159 (45.3%)
− 22 (100%) 192 (54.7%)
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NS, 
not significant.
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into nude mice. Only the variant E3;ins53A20-expressing 
clones formed tumors but not the mock-transfected clones 
(p = 0.0026; Fig. 3), confirming the potent transforming abil-
ity of variant E3;ins53A20.
DISCUSSION
To date, multiple ALK fusion genes have been identified 
in human cancer, including the fusion of ALK with NPM,1 
TFG,14 CLTC,27 ATIC,28 CARS,29 MSN,30 TPM3,31 EML4,17 
KIF5B,15 KLC1,16 and C2orf44.32 In lung cancer, the primary 
ALK fusion partners were reported to be EML4, followed by 
KIF5, TFG, and KLC1. The fusion point of ALK is conserved 
among most of the chimeric proteins, resulting in the fusion 
of the entire intracellular kinase domain of ALK to the corre-
sponding partner. In this study, we reported the detection of a 
novel EML4-ALK variant (E3;ins53A20) in a lung ADC, with 
strong ALK protein expression and breakapart FISH signals. 
The novel variant involved an inframe fusion between EML4 
exon 3 and 53 bp upstream of ALK exon 20, comprising the 
coiled-coil domain of EML4, and the juxtamembrane intra-
cellular region of ALK, including the entire tyrosine kinase 
domain. The EML4 portion of this novel variant comprised 
only the basic coiled-coil domain, which is always preserved 
in all reported EML4-ALK fusion variants. Its constitutive 
expression in lung is believed to play an essential role in the 
dimerization and activation of downstream oncogenic effects 
of EML4-ALK isoforms.6 The potent transformation poten-
tial of variant E3;ins53A20 has been confirmed by in vivo 
tumorigenicity assay. It is likely to play an important role in 
the tumorigenesis of lung cancer. The reported EML4-ALK 
fusion genes comprised variable truncations of EML4 (occur-
ring at exons 2, 6, 13, 14, 15, 18, and 20), and the kinase 
domain of ALK and all demonstrated gain of function proper-
ties. Identification of E3;ins53A20 as an alternative EML4-
ALK variant further consolidates the role of ALK signaling 
in lung cancers.
FIGURE 3.  Transforming potential of the novel EML4-ALK variant E3;ins53A20 (Ref. No. 3081). A, NIH 3T3 mouse embryo 
fibroblast cells were transfected with EML4-ALK variant E3;ins53A20 or empty vector. The ectopic expression of the fusion 
protein in NIH 3T3 cells was determined by Western blot analysis, using anti-ALK antibody. B, Nude mice were injected subcu-
taneously with the variant E3;ins53A20-expressing cells and mock-transfected cells on the right and left side of the dorsal flank, 
respectively. Tumor formation was examined after 3 weeks. C, Schematic illustration of the structure of novel EML4-ALKvariant. 
D, ALK Immunohistochemistry, Fluorescent in situ hybridization and sequence of the novel EML4-ALK variant E3;ins53A20. ALK, 
anaplastic lymphoma kinase, EML4, echinoderm microtubule-associated protein-like.
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After the recent discovery of ALK rearrangement in 
lung cancer, ALK inhibition has been emerging as a promising 
targeted therapy for this subset of patients. Identification of 
appropriate patient population is the key to the overall success 
of such targeted therapy. A variety of methods can be used for 
the detection of ALK rearrangements, including FISH, IHC, 
and RT-PCR. Each method, inevitably, has its own advantages 
and disadvantages. FISH has been adopted as the method of 
choice for patient selection in clinical trials. The breakapart 
probe allows detection of rearrangements, independent of 
the fusion partners or specific breakpoint. However, FISH 
requires specialized laboratory techniques, expert interpreta-
tion, relatively high costs, and a longer turnaround time. The 
current criteria, for a positive FISH result, that has been set 
for clinical trial is that more than 15% of the tumor cells must 
show split red and green signals, separated by at least two sig-
nal diameters, or a single red signal.18,33
An alternative to FISH is IHC. Similar to the FISH 
assay, IHC can detect ALK independent of the fusion part-
ner. However, researchers found it difficult to reliably detect 
EML4-ALK protein expression in NSCLC. The detection 
threshold of IHC depends on the tissue preparation, affinity of 
the antibody, the sensitivity of detection system used, the scor-
ing system, and experience of the scorer. Unlike the strong 
expression of ALK protein in anaplastic large-cell lymphoma, 
which can be readily detected by IHC, ALK antibodies seem 
to give variable results in lung cancer. The early studies, using 
commercial ALK antibodies and standard protocol, showed 
that IHC was specific but not sensitive for the detection of 
lung cancer with ALK rearrangement.12,34 The low sensitivity 
may be attributed to the low level of EML4 transcriptional 
activity or to instability of EML4-ALK in cells.6 A variety 
of signal amplification technologies have been developed 
to improve the sensitivity of ALK protein detection in lung 
cancer, including tyramide amplification19 and intercalation 
of an antibody-enhanced polymer.15 Using the highly sensi-
tive detection methods in combination with high affinity 
antibodies, for example, 5A4 and D5F3, IHC can effectively 
detect ALK fusion protein in lung ADCs with high sensitiv-
ity and specificity.20,34,35 Multiplex RT-PCR system has been 
the usual screening strategy applied for ALK gene rearrange-
ments,6,7,36,37 and has been considered the least subjective. The 
presence of fusion transcripts as detected by RT-PCR provides 
direct evidence of chromosomal translocation. However, the 
requirement of high-quality RNA makes it difficult to imple-
ment in a routine clinical diagnostic laboratory, using FFPE 
samples. Furthermore, RT-PCR can only detect fusion tran-
scripts with known fusion partners.
Given that IHC is a routine methodology in most pathol-
ogy laboratories to detect a protein of interest, it is desirable to 
establish a sensitive and accurate detection method for ALK 
fusion protein based on IHC. In this study, we reported the 
immunohistochemical detection of ALK protein expression 
in 22 of 373 lung ADCs. The staining was considered spe-
cific as all ALK IHC-positive cases were confirmed to harbor 
ALK rearrangement either by FISH or by RT-PCR analysis. 
Two-tier systems for the evaluation of ALK status with initial 
IHC screening followed by FISH analysis of IHC score 2+, or 
both 1+ and 2+ cases have been proposed.21,22 However, we did 
not observe a background or nonspecific staining using our 
staining protocol, consistent with the biological fact that ALK 
protein is not constitutively expressed in normal lung tissue. 
The positive cases showed diffuse and strong immunoreactiv-
ity that were scored as 3+ according to the combined intensity 
and proportion scoring criteria. The strong immunoreactivity 
in ALK-positive cases would be extremely helpful in avoiding 
interobserver variation in the assessment of ALK IHC status.
It has been reported that some of the ALK IHC-positive 
tumors that had been confirmed by RT-PCR showed no break-
apart FISH signals.19,34 In our cases series, two cases dem-
onstrated false-negative FISH results, despite repeat testing. 
The EML4-ALK chimeric proteins are the result of inversions 
within the short arm of chromosome 2, involving 2p21 and 
2p23, approximately 12 megabases apart. Because the EML4 
and ALK loci are mapped relatively close on chromosome 
2p, the subtle changes in fluorescent signal, caused by intra-
chromosomal inversion in some positive cases, might be dif-
ficult to interpret and might lead to false-negative results. The 
limited probe separation in such cases reduces the sensitiv-
ity of FISH assay. Peled et al.38 reported a crizotinib-sensitive 
NSCLC with complex ALK rearrangement that was negative 
by FISH analysis. Next-generation sequencing analysis of 
the tumor DNA revealed multiple breakpoints and complex 
rearrangement at genomic level, which was not detected by 
breakapart FISH assay. Nevertheless, high concordant rates 
between FISH and IHC have been reported, using high affinity 
antibodies and sensitive visualization systems.
In conclusion, we report that IHC is a sensitive and spe-
cific detection method to detect ALK rearrangement in lung 
cancer. IHC would be served as an effective and rapid detec-
tion method in routine pathologic laboratories for the iden-
tification of suitable candidates for ALK-targeted therapy. In 
addition, we reported a novel oncogenic EML4-ALK variant 
(E3;ins53A20). Our series demonstrated that some ALK IHC-
positive but FISH-negative lung cancers did harbor the trans-
location events as confirmed by RT-PCR. Thus, this subgroup 
of patients should also benefit from ALK inhibitory therapy. 
Further clinical trials are required to address the predictive 
value of ALK IHC in these patients.
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